Neurological disorders such as Parkinson’s disease, Alzheimer’s disease, and depression pose significant challenges in the field of medicine due to their complex nature and the difficulty associated with early detection. These conditions affect millions of people worldwide, causing significant impairments in cognitive and motor functions, leading to a decline in quality of life. Despite advancements in medical science, detecting these disorders in their early stages remains a daunting task, primarily due to the absence of definitive and easily accessible diagnostic methods.

Parkinson’s disease, for instance, is a progressive neurological disorder that affects movement, causing tremors, stiffness, and balance issues. It is estimated that around 10 million people worldwide suffer from Parkinson’s, and statistics indicate that one in every hundred individuals over the age of 60 is diagnosed with the condition. The major concern with Parkinson’s disease is that it often remains undetected for five to ten years after its onset, significantly reducing the effectiveness of treatment strategies. Early symptoms, such as mild tremors, subtle speech changes, and slight balance problems, are often overlooked or mistaken for normal aging processes, delaying medical intervention.

The diagnostic process for Parkinson’s disease is expensive and time-consuming. Traditional methods rely on clinical evaluations, neurological exams, and in some cases, advanced imaging techniques such as MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. These tests are not only costly but also require specialized medical facilities and trained professionals, making them inaccessible to a large portion of the global population. In India, for example, a biological test for Parkinson’s costs a minimum of 35,000 rupees, making it financially burdensome for many patients, especially those from low-income backgrounds.

Similarly, Alzheimer’s disease, another progressive neurolog